GlassScriptPhysician profile
Connor D Healey
NPI 1316206998
$4,952.99
in general payments reported to CMS, 2019-2025
30 companies · $944 in 2025
The $944 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $347 · 2021: $245 · 2022: $556 · 2023: $782 · 2024: $871 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,597.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,400.39 | 2019-2025 | |
| Pfizer INC. | $494.37 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $354.05 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $312.82 | 2019-2025 | Wainua, Farxiga, Lokelma |
| Amgen INC. | $256.71 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.89 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $227.77 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $221.04 | 2021-2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $190.45 | 2021-2025 | Verquvo, Capvaxive |
| Kiniksa Pharmaceuticals International, Plc | $145.17 | 2024 | Arcalyst |
| Abbott Laboratories | $140.96 | 2019-2024 | Mitraclip |
| Cvrx, INC. | $129.15 | 2023-2025 | Barostim Neo System |
| Abiomed | $97.80 | 2019 | |
| Alnylam Pharmaceuticals INC. | $94.18 | 2023-2025 | Onpattro |
| Lexicon Pharmaceuticals, INC. | $72.23 | 2023-2024 | Inpefa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $70.43 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.36 | 2019-2024 | Lifevest |
| Chiesi USA, INC. | $61.56 | 2019 | |
| Sanofi-Aventis U.S. LLC | $56.52 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $55.75 | 2019 | |
| Astellas Pharma US INC | $44.52 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $36.15 | 2019 | |
| Esperion Therapeutics, INC. | $35.40 | 2022-2025 | Nexletol |
| Portola Pharmaceuticals, LLC | $24.41 | 2019 | |
| Gilead Sciences, INC. | $24.36 | 2019 | |
| Agios Pharmaceuticals, INC. | $23.65 | 2025 | Pyrukynd |
| Bayer Healthcare Pharmaceuticals INC. | $20.55 | 2023 | |
| Boston Scientific Corporation | $18.56 | 2019 | |
| Bridgebio Pharma, INC. | $18.45 | 2025 | Attruby |
| Amarin Pharma, INC. | $18.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connor Healey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.